A Novel Method of Nanoparticle Delivery to Brain by Targeting Ec-gp96
A Novel Method of Nanoparticle Delivery to Brain by Targeting Ec-gp96
批准号:
8078838
负责人:
MARK E DAVIS
金额:
$31.85万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-04-01 至 2013-03-31
关键词:
AffectAffinityAgonistAnimal ModelAnimalsAntibodiesBacteriaBindingBinding SitesBloodBlood - brain barrier anatomyBrainBrain DiseasesCarrier ProteinsCell LineCentral Nervous System AgentsCharacteristicsComputer SimulationCoupledDiseaseDrug Delivery SystemsEndothelial CellsEscherichia coliExtravasationFluorescent DyesGoldHumanIn VitroLigandsLiposomesLocationMalignant NeoplasmsMembrane ProteinsMeningitisMetabolismMethodsMonitorMotivationMusNeuraxisNewborn InfantOrganPharmaceutical PreparationsPharmacologic SubstancePhasePhase II Clinical TrialsProcessProteinsStagingStructureSystemTestingTherapeuticTight JunctionsTimeToxinVirusbasebrain tissuedesigndrug developmentefflux pumpfirewallin vitro Modelin vivomonolayernanoparticlenovelparticlepreventpublic health relevancereceptorreceptor expressionsmall moleculeuptakevector
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): A Novel Method of Nanoparticle Delivery to Brain by Targeting Ec-gp96 ABSTRACT The blood brain barrier (BBB) is composed of brain microvascular endothelial cells connected each other with tight junction molecules thereby, making the barrier impermeable to toxins, bacteria, viruses, and other unwanted substance from blood. This specific characteristic feature of the BBB along with efflux pumps prevents the delivery of therapeutic compound to treat brain diseases. Although, several methods have been identified to target the central nervous system for drug delivery, non-specificity is a major problem with these strategies. One of the critical challenges in drug development is the delivery of drugs to the central nervous system (CNS) across the BBB. E. coli studies by Nemani group, performed using both an in vitro model of human brain microvascular endothelial cells and in newborn mice, have been used to identified a BBB specific receptor, Ec-gp96 to which E. coli K1, a meningitis causing bacterium binds and enters the brain. This interaction occurs between outer membrane protein A of E. coli and Ec-gp96 for binding to and entry of the BBB. The computer modeling studies of OmpA-Ec-gp96 interaction by Goddard group have predicted several compounds compatible with the binding to Ec-gp96. Of these several have been shown to be effective in preventing the binding of OmpA of E. coli with Ec-gp6 and thus inhibiting the invasion of the bacteria in HBMEC. This has identified for the first time small molecule ligands for Ec-gp96. Furthermore, Davis group has developed CDP nanoparticles to deliver drugs or other payloads to treat cancers and some of the methods are being tested in Phase I and Phase II clinical trials. These exciting experimental results set the stage for this proposal which will design Ec-gp96 targeting ligands and conjugate them to nanoparticles to develop a delivery system specifically targeting the blood-brain barrier.
PUBLIC HEALTH RELEVANCE: This proposal is aimed at designing ligands targeting a protein only found in the cells lining the blood-brain barrier, that will be used to make a drug-delivery system based on nanoparticles to specifically deliver drugs into the brain.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Project 1: Targeted Nanoparticle Therapeutics for Treating Intracranial Disease
-
批准号:8962030
-
项目类别:
-
资助金额:$24.08万
-
财政年份:2015
-
负责人:MARK E DAVIS
-
依托单位:
In Vivo Pharmacodynamics of RNAi-based Cancer Therapies
-
批准号:7983569
-
项目类别:
-
资助金额:$18.25万
-
财政年份:2010
-
负责人:MARK E DAVIS
-
依托单位:
A Novel Method of Nanoparticle Delivery to Brain by Targeting Ec-gp96
-
批准号:8246434
-
项目类别:
-
资助金额:$32.03万
-
财政年份:2010
-
负责人:MARK E DAVIS
-
依托单位:
A Novel Method of Nanoparticle Delivery to Brain by Targeting Ec-gp96
-
批准号:7949884
-
项目类别:
-
资助金额:$33.32万
-
财政年份:2010
-
负责人:MARK E DAVIS
-
依托单位:
Design of Gene Delivery System to Target Hepatocytes
-
批准号:7347036
-
项目类别:
-
资助金额:$37.86万
-
财政年份:2005
-
负责人:MARK E DAVIS
-
依托单位:
Design of Gene Delivery System to Target Hepatocytes
-
批准号:7011210
-
项目类别:
-
资助金额:$37.5万
-
财政年份:2005
-
负责人:MARK E DAVIS
-
依托单位:
Design of Gene Delivery System to Target Hepatocytes
-
批准号:7172284
-
项目类别:
-
资助金额:$37.51万
-
财政年份:2005
-
负责人:MARK E DAVIS
-
依托单位:
Design of Gene Delivery System to Target Hepatocytes
-
批准号:6862243
-
项目类别:
-
资助金额:$38.77万
-
财政年份:2005
-
负责人:MARK E DAVIS
-
依托单位:
Brain Endothelial Cell Receptor for Escherichia coli
-
批准号:8291201
-
项目类别:
-
资助金额:$44.81万
-
财政年份:1997
-
负责人:MARK E DAVIS
-
依托单位:
Brain Endothelial Cell Receptor for Escherichia coli
-
批准号:8689878
-
项目类别:
-
资助金额:$44.78万
-
财政年份:1997
-
负责人:MARK E DAVIS
-
依托单位:
Brain Endothelial Cell Receptor for Escherichia coli
-
批准号:8490275
-
项目类别:
-
资助金额:$42.11万
-
财政年份:1997
-
负责人:MARK E DAVIS
-
依托单位:
Brain Endothelial Cell Receptor for Escherichia coli
-
批准号:8878982
-
项目类别:
-
资助金额:$44.77万
-
财政年份:1997
-
负责人:MARK E DAVIS
-
依托单位:
Brain Endothelial Cell Receptor for Escherichia coli
-
批准号:8186067
-
项目类别:
-
资助金额:$46.65万
-
财政年份:1997
-
负责人:MARK E DAVIS
-
依托单位:
In Vivo Pharmacodynamics of RNAi-based Cancer Therapies
-
批准号:8545712
-
项目类别:
-
资助金额:$16.19万
-
财政年份:--
-
负责人:MARK E DAVIS
-
依托单位:
In Vivo Pharmacodynamics of RNAi-based Cancer Therapies
-
批准号:8707992
-
项目类别:
-
资助金额:$16.66万
-
财政年份:--
-
负责人:MARK E DAVIS
-
依托单位:
In Vivo Pharmacodynamics of RNAi-based Cancer Therapies
-
批准号:8324028
-
项目类别:
-
资助金额:$17.46万
-
财政年份:--
-
负责人:MARK E DAVIS
-
依托单位:
In Vivo Pharmacodynamics of RNAi-based Cancer Therapies
-
批准号:8380721
-
项目类别:
-
资助金额:$17.46万
-
财政年份:--
-
负责人:MARK E DAVIS
-
依托单位:
海外基金